Merck & Co., Inc. (NYSE:MRK) Shares Sold by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC cut its stake in Merck & Co., Inc. (NYSE:MRK) by 2.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,301 shares of the company’s stock after selling 1,815 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $8,665,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of MRK. Itau Unibanco Holding S.A. acquired a new stake in Merck & Co., Inc. during the 2nd quarter valued at $39,000. Abich Financial Wealth Management LLC boosted its position in Merck & Co., Inc. by 121.8% in the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the last quarter. Quarry LP purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at about $42,000. Strategic Financial Concepts LLC grew its stake in shares of Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after acquiring an additional 32,832 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 47.5% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after acquiring an additional 122 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.2 %

NYSE:MRK opened at $98.31 on Friday. The firm has a market capitalization of $248.69 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.41 and a beta of 0.40. The business has a 50 day simple moving average of $109.68 and a 200 day simple moving average of $119.35. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. Merck & Co., Inc. has a 12-month low of $97.90 and a 12-month high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $16.66 billion during the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.13 earnings per share. Equities research analysts predict that Merck & Co., Inc. will post 7.75 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Sanford C. Bernstein assumed coverage on Merck & Co., Inc. in a report on Thursday, October 17th. They issued a “market perform” rating and a $115.00 price target for the company. Guggenheim reduced their target price on Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. BMO Capital Markets dropped their price target on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Citigroup reduced their price objective on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, UBS Group decreased their price objective on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $130.86.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.